HIGHLIGHTS INOVIQ focused on advancing its SubB2M and EXO-NET programs during the year with these efforts culminating in clinical validation of its SubB2M technology platform and a commercial deal for its EXO-NET exosome capture technology. These important milestones and other development and commercial progress are highlighted below. Research & Development – Completed analytical validation of SubB2M-CA15-3 test evidencing assay reproducibility and providing initial data showing discrimination of both early and late-stage breast cancer from healthy controls – Successful clinical validation of SubB2M/ CA15-3 test demonstrating detection of all stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%) – Contract Research Agreement signed with Nicoya to develop SubB2M-based Surface Plasmon Resonance (SPR) test on the Alto™ Digital SPR instrument – High-Throughput (HT) EXO-NET exosome capture system completed – EXO-NET® feasibility study by University of Queensland confirmed utility of EXONET for isolating Extracellular Vesicle (EV) biomarkers and development of an EV-based ovarian cancer screening test – Post year-end, serum equivalence study reported EXO-NET successfully captured EVs in plasma and serum, but long-stored biobank unsuitable for EV biomarker discovery and validation Commercial – Percorso Life Sciences engaged to provide US-based contract sales and logistics services for INOVIQ products – EXO-NET sales campaign implemented in the USA targeting academic researchers to gain scientific support – New EXO-NET data presented at the International Society for Extracellular Vesicles (ISEV) Annual Meeting 2023 in Seattle, USA confirming its effectiveness and broad utility across multiple biofluids – Post year-end, INOVIQ and Promega Corporation signed a global joint marketing agreement for INOVIQ’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems – Direct sales model established for hTERT in the USA – US patents granted for SubB2M and hTERT technologies Review of Operations 6 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3